Miyazaki: ‘Yellowtail Mansion’ to Be Designated as National Important Cultural Property

The Hidaka residence appears to “float” in Akamizu Bay in Nobeoka, Miyazaki Prefecture.
11:12 JST, July 15, 2023
NOBEOKA, Miyazaki — A residence locally known as the “yellowtail mansion” is expected to be designated as a national important cultural property.
The Hidaka residence was built by Kameichi Hidaka (1845-1917), who headed a group of yellowtail fishermen in Nobeoka, Miyazaki Prefecture. He made his fortune through a fishing method he invented and started building the house from 1887 by reclaiming the coast to make a fish-landing site.
Throughout the early 20th century, the building was repeatedly expanded and remodeled to its current architecture.
The Japanese-style building — a two-story wooden structure with a total floor space of 772 square meters — has a 20-tatami-mat hall, a back room with a view of the sea and mountains, and a kitchen where a large kamado stove remains. Next to the mansion sits a brick smokery where landed yellowtail were processed. The property conveys the liveliness of the bygone fishery industry.
Currently, Kameichi’s descendants live in the mansion and it is also used as a ryotei traditional Japanese restaurant.
Related Tags
Top Articles in Features
-
Tokyo’s New Record-Breaking Fountain Named ‘Tokyo Aqua Symphony’
-
High-Hydration Bread on the Rise, Seeing Increase in Specialty Shops, Recipe Searches
-
Japanese Students Use Traditional Pickle to Create Novel Wagashi Confectionery
-
Heirs to Kyoto Talent: Craftsman Works to Keep Tradition of ‘Kinran’ Brocade Alive Through Initiatives, New Creations
-
My Spendthrift Mother Constantly Asks Me for Money
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Videos Plagiarized, Reposted with False Subtitles Claiming ‘Ryukyu Belongs to China’; Anti-China False Information Also Posted in Japan
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

